Press Release

Mount Sinai Entered into Exclusive License Agreement for Neutralizing SARS-CoV-2 Antibody Derived from Harbour BioMed Technology

July 21, 2021

Back to list

Mount Sinai Entered into Exclusive License Agreement for Neutralizing SARS-CoV-2 Antibody Derived from Harbour BioMed Technology

July 21, 2021

Cambridge, MA, Rotterdam, NL, Shanghai/Suzhou, CN – July 21, 2021

 

Harbour BioMed (“HBM”, HKEX: 02142) today announced that the Icahn School of Medicine at Mount Sinai in New York, NY has developed a collection of the COVID-19 virus neutralizing antibodies through a collaboration with Harbour BioMed US, Inc. (a subsidiary of Harbour BioMed). Subsequently, Icahn Mount Sinai has entered into an Exclusive License Agreement with a third party for a collection of antibodies having COVID-19 neutralizing properties.

 

About Harbour BioMed


 
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.


 
The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.  


 
For more information, please visit www.harbourbiomed.com

Media and Investor Contact:

Harbio BioMed Public Relations

Phone: +86-21-53399123

E-mail: pr@harbourbiomed.com